J Clin Med. 2016 Mar 7;5(3). pii: E34. doi: 10.3390/jcm5030034.
Stanley Dudrick's Memorial Hospital, General Surgery Unit, Skawina 32-050, Poland. klek at poczta.onet.pl.
Items in both categories Omega-3 and Trauma Surgery are:
- Hospitalization costs reduced ~3,000 dollars when intravenous nutrition was augmented with Omega-3 – Aug 2019
- Omega-3 supplements taken before and after surgery actually helped – RCT Nov 2018
- ICU length of stay reduced when supplement with Omega-3 – meta-analysis July 2018
- 3 days of Omega-3 before cardiac surgery reduced risk of post-op bleeding by half – RCT March 2018
- Omega-3 benefits in surgery and ICU including via IV - March 2016
- Omega-3 reduced time in hospital and atrial fibrillation after cardiac surgery – meta-analysis May 2016
- 2.7 fewer days in hospital after surgery if had taken Omega-3 (19 RCT) – meta-analysis – June 2017
- Sepsis: 4 fewer days in ICU if add Omega-3 – meta-analysis of 12 RCT – June 2017
- Cognitive decline after traumatic brain injury reduced by Omega-3 (mice) – Nov 2016
- Football Brain injuries prevented by Omega-3 – RCT Jan 2016
- Omega-3 should be cost-effective to reduce days in ICU – simulation June 2015
Intravenous lipid emulsions are an essential component of parenteral nutrition regimens. Originally employed as an efficient non-glucose energy source to reduce the adverse effects of high glucose intake and provide essential fatty acids, lipid emulsions have assumed a larger therapeutic role due to research demonstrating the effects of omega-3 and omega-6 polyunsaturated fatty acids (PUFA) on key metabolic functions, including
- inflammatory and
- immune response,
- coagulation, and
- cell signaling.
Indeed, emerging evidence suggests that the effects of omega-3 PUFA on inflammation and immune response result in meaningful therapeutic benefits in
- cancer, and
- critically ill patients as well as patients
- requiring long-term parenteral nutrition.
The present review provides an overview of the mechanisms of action through which omega-3 and omega-6 PUFA modulate the immune-inflammatory response and summarizes the current body of evidence regarding the clinical and pharmacoeconomic benefits of intravenous n-3 fatty acid-containing lipid emulsions in patients requiring parenteral nutrition.
PMID: 26959070 PMCID: PMC4810105 DOI: 10.3390/jcm5030034
Clipped from PDF
- “ . . analyzed patient outcomes and hospital economic data from Italian, French, German, and UK
hospitals using a discrete event simulation scheme and demonstrated that treatment costs were entirely
offset by reductions in antibiotic use and the length of hospital stay”